Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Cartessa Aesthetics, a premier North American aesthetic medical device company, has partnered with Classys, Inc, a global aesthetics business leader based in South Korea, to bring EVERESSE by Volnewmer, their world class monopolar radiofrequency technology, to the US market.

Classys, which is listed on the KOSDAQ, is one of South Korea’s most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys’s official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

“As the world’s largest energy-based devices (EBD) market, our search for an ideal partner in the U.S. was pivotal and we are excited to join forces with Cartessa. With remarkable growth over the past eight years, Cartessa has demonstrated exceptional commercial strength and an expansive network across multiple customer segments,” says Seung Han Baek, CEO of Classys, Inc.

Designed to overcome patient and provider pain points with legacy monopolar radiofrequency technologies, EVERESSE is a cutting-edge solution to combat skin laxity and smooth fine lines and wrinkles – with maximum efficacy and minimal discomfort. Leveraging Targeted Thermal Precision Technology, EVERESSE’s thermal RF energy is delivered to both the papillary and reticular dermis, while safeguarding the epidermis. This “double depth” approach triggers greater tissue coagulation and new collagen production as a mechanism of action to visibly lift and tighten the skin.

A significant advancement over earlier technologies is how comfortable the EVERESSE treatment is. Instead of multi-pulse energy delivery common with other devices, EVERESSE delivers a single pulse of consistent RF energy coupled with continuous water cooling to improve patient safety and comfort. The unique curved and tilted tip head adapts to the curvature of the treatment area, ensuring continuous stable contact between the tip and the skin. The many technological innovations built into EVERESSE contribute to more efficient energy delivery as well as a faster and more comfortable treatment.

With EVERESSE, providers have two handpieces and can easily customize treatments – choosing between tips to treat the face or smaller areas including around the eyes. Visible skin lifting and tightening can be seen immediately; optimal results are observed around 8 weeks and 12 weeks.

“There has been limited meaningful innovation in the monopolar RF market – treatments are painful for patients and expensive consumables and long treatment times create headaches for providers. Our goal with EVERESSE – as with all our technologies – is to bring devices to market that deliver on an unmet need and offer superior clinical efficacy, patient experience, and return on investment. Working alongside Classys, a world-class leader in energy-based devices, we expect to shake up the U.S. monopolar RF market with EVERESSE in the same way we’ve done for CO2 and laser hair removal,” says Gabe Lubin, Founder & CEO of Cartessa Aesthetics.

“Recognizing that skin tightening and rejuvenation are the fastest-growing indications in the U.S., we are confident that EVERESSE will meet the unique needs of this market. Our advanced, non-invasive solution offers safe and comfortable treatments for patients of all skin types, delivering immediate and lasting skin tightening and lifting results. We look forward to expanding our presence in the U.S. and establishing EVERESSE as the new gold standard in skin tightening and lifting,” adds Seung Han Baek, CEO of Classys, Inc.

Hot this week

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.